• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新辅助放化疗和根治性手术后局部晚期直肠癌的病理完全缓解可能低估远处转移:发生率、转移模式和危险因素。

Pathological complete response may underestimate distant metastasis in locally advanced rectal cancer following neoadjuvant chemoradiotherapy and radical surgery: Incidence, metastatic pattern, and risk factors.

机构信息

Department of Colorectal Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, PR China.

Department of Pathology, Fujian Medical University Union Hospital, Fuzhou, Fujian, PR China.

出版信息

Eur J Surg Oncol. 2019 Jul;45(7):1225-1231. doi: 10.1016/j.ejso.2019.03.005. Epub 2019 Mar 9.

DOI:10.1016/j.ejso.2019.03.005
PMID:30879932
Abstract

AIM

To evaluate the pattern of tumor relapse of pathological complete response (pCR) patients with locally advanced rectal cancer (LARC) following neoadjuvant chemoradiotherapy (nCRT) and total mesorectal excision (TME), and to identify predictive factors of distant metastasis in pCR patients after nCRT.

METHOD

This was a retrospective analysis of 118 LARC patients who achieved a pCR following nCRT and TME from 2008 to 2015. Clinicopathological and therapeutic parameters were evaluated as possible predictors of distant metastasis-free survival (DMFS), and COX regression analysis was performed.

RESULTS

After a median follow-up of 57 months, the 5-year overall and disease-free survival rates were 94.7% and 88.1%, respectively. Overall, 6 patients (5.1%) died, no local recurrence occurred, 13 patients (11%) developed distant metastases, including lung (n = 5), liver (n = 2), bone (n = 3), lung and brain (n = 1), peritoneal (n = 1), and spleen (n = 1) metastasis. On univariate analysis, tumor distance from the anal verge (HR = 0.706, P = 0.039), acellular mucin pools (HR = 6.687, P = 0.002), and MUC1 expression (HR = 8.280, P < 0.001) were independently associated with DMFS. COX regression demonstrated that MUC1 expression (HR = 3.812, P = 0.041) remained to be an independent predictor of DMFS in pCR patients.

CONCLUSION

Distant metastasis still remained a major concern in pCR patients following nCRT and TME. Tumor distance from the anal verge, acellular mucin pools, and MUC1 expression were associated with distant metastasis in patients with pCR. MUC1 staining remained to be an independent risk factor for DMFS. Such information could facilitate treatment decision in these patients, such as adjuvant chemotherapy and follow-up.

摘要

目的

评估接受新辅助放化疗(nCRT)和全直肠系膜切除术(TME)后病理完全缓解(pCR)的局部进展期直肠癌(LARC)患者的肿瘤复发模式,并确定 nCRT 后 pCR 患者发生远处转移的预测因素。

方法

这是一项回顾性分析,纳入了 2008 年至 2015 年间 118 例接受 nCRT 和 TME 后达到 pCR 的 LARC 患者。评估了临床病理和治疗参数作为无远处转移生存(DMFS)的可能预测因素,并进行 COX 回归分析。

结果

中位随访 57 个月后,患者 5 年总生存率和无病生存率分别为 94.7%和 88.1%。总体而言,有 6 例(5.1%)患者死亡,无局部复发,13 例(11%)患者发生远处转移,包括肺(n=5)、肝(n=2)、骨(n=3)、肺和脑(n=1)、腹膜(n=1)和脾(n=1)转移。单因素分析显示,肿瘤距肛缘距离(HR=0.706,P=0.039)、无细胞黏液池(HR=6.687,P=0.002)和 MUC1 表达(HR=8.280,P<0.001)与 DMFS 独立相关。COX 回归分析表明,MUC1 表达(HR=3.812,P=0.041)仍然是 pCR 患者 DMFS 的独立预测因素。

结论

在接受 nCRT 和 TME 治疗后,pCR 患者仍存在远处转移的主要问题。肿瘤距肛缘距离、无细胞黏液池和 MUC1 表达与 pCR 患者的远处转移有关。MUC1 染色仍然是 DMFS 的独立危险因素。这些信息可以为这些患者的治疗决策提供帮助,如辅助化疗和随访。

相似文献

1
Pathological complete response may underestimate distant metastasis in locally advanced rectal cancer following neoadjuvant chemoradiotherapy and radical surgery: Incidence, metastatic pattern, and risk factors.新辅助放化疗和根治性手术后局部晚期直肠癌的病理完全缓解可能低估远处转移:发生率、转移模式和危险因素。
Eur J Surg Oncol. 2019 Jul;45(7):1225-1231. doi: 10.1016/j.ejso.2019.03.005. Epub 2019 Mar 9.
2
[Comparison of long-term efficacy between watch and wait strategy and total mesorectal excision in locally advanced rectal cancer patients with clinical complete response after neoadjuvant therapy].[新辅助治疗后临床完全缓解的局部晚期直肠癌患者中观察等待策略与全直肠系膜切除术的长期疗效比较]
Zhonghua Wei Chang Wai Ke Za Zhi. 2020 Mar 25;23(3):266-273. doi: 10.3760/cma.j.cn.441530-20200224-00081.
3
[Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].[局部晚期高危直肠癌患者新辅助综合治疗的疗效与安全性分析]
Zhonghua Wei Chang Wai Ke Za Zhi. 2019 Apr 25;22(4):349-356. doi: 10.3760/cma.j.issn.1671-0274.2019.04.007.
4
Improved Metastasis- and Disease-Free Survival With Preoperative Sequential Short-Course Radiation Therapy and FOLFOX Chemotherapy for Rectal Cancer Compared With Neoadjuvant Long-Course Chemoradiotherapy: Results of a Matched Pair Analysis.与新辅助长疗程放化疗相比,术前序贯短疗程放疗联合FOLFOX化疗改善直肠癌患者的转移和无病生存率:配对分析结果
Int J Radiat Oncol Biol Phys. 2017 Oct 1;99(2):417-426. doi: 10.1016/j.ijrobp.2017.05.048. Epub 2017 Jun 6.
5
[Comparison of short-term efficacy and perioperative safety between neoadjuvant therapy and total neoadjuvant therapy in patients with locally advanced rectal cancer].局部晚期直肠癌患者新辅助治疗与全新辅助治疗的短期疗效及围手术期安全性比较
Zhonghua Wei Chang Wai Ke Za Zhi. 2020 Mar 25;23(3):274-280. doi: 10.3760/cma.j.cn.441530-20190819-00312.
6
Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management.直肠癌的器官保留:一项II期随机对照试验,评估接受放化疗加诱导或巩固化疗以及全直肠系膜切除术或非手术治疗的局部晚期直肠癌患者的3年无病生存率。
BMC Cancer. 2015 Oct 23;15:767. doi: 10.1186/s12885-015-1632-z.
7
[Preoperative chemoradiotherapy for rectal cancer: experience from one centre].[直肠癌术前放化疗:来自一个中心的经验]
Cancer Radiother. 2015 Apr;19(2):98-105. doi: 10.1016/j.canrad.2014.11.011. Epub 2015 Mar 10.
8
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.奥沙利铂联合氟尿嘧啶为基础的术前放化疗和局部进展期直肠癌术后化疗(德国 CAO/ARO/AIO-04 研究):多中心、开放标签、随机、III 期临床试验的最终结果。
Lancet Oncol. 2015 Aug;16(8):979-89. doi: 10.1016/S1470-2045(15)00159-X. Epub 2015 Jul 15.
9
Clinical Analysis of the Efficacy and Safety of Different Neoadjuvant Strategies in the Treatment of Locally Advanced Rectal Cancer.局部晚期直肠癌不同新辅助策略治疗的疗效和安全性临床分析。
Cancer Invest. 2024 Aug;42(7):661-670. doi: 10.1080/07357907.2024.2381197. Epub 2024 Jul 22.
10
Prognosis factors for recurrence in patients with locally advanced rectal cancer preoperatively treated with chemoradiotherapy and adjuvant chemotherapy.局部进展期直肠癌患者术前接受放化疗和辅助化疗后复发的预后因素。
Dis Colon Rectum. 2013 Apr;56(4):416-21. doi: 10.1097/DCR.0b013e318274d9c6.

引用本文的文献

1
Correspondence for the article titled "Predictive value of rectal MRI variables for pathological complete response in locally advanced rectal cancer following neoadjuvant chemoradiotherapy".题为《新辅助放化疗后局部晚期直肠癌直肠MRI变量对病理完全缓解的预测价值》的文章的通信
Int J Colorectal Dis. 2025 Jun 4;40(1):135. doi: 10.1007/s00384-025-04925-7.
2
Predictive value of rectal MRI variables for pathological complete response in locally advanced rectal cancer following neoadjuvant chemoradiotherapy.新辅助放化疗后局部晚期直肠癌直肠MRI变量对病理完全缓解的预测价值
Int J Colorectal Dis. 2025 Feb 17;40(1):42. doi: 10.1007/s00384-024-04801-w.
3
Does the initial treatment of primary tumor impact prognosis after recurrence in locally advanced rectal cancer? Results from a retrospective cohort analysis.
局部进展期直肠癌复发后初始治疗对肿瘤的影响是否影响预后?一项回顾性队列分析的结果。
Int J Colorectal Dis. 2024 Sep 28;39(1):153. doi: 10.1007/s00384-024-04721-9.
4
Clinical significance of adjuvant chemotherapy for pathological complete response rectal cancer patients with acellular mucin pools after neoadjuvant chemoradiotherapy.新辅助放化疗后伴有无细胞粘蛋白池的病理完全缓解直肠癌患者辅助化疗的临床意义
Therap Adv Gastroenterol. 2023 Feb 3;16:17562848221117875. doi: 10.1177/17562848221117875. eCollection 2023.
5
Combination of Changes in CEA and CA199 Concentration After Neoadjuvant Chemoradiotherapy Could Predict the Prognosis of Stage II/III Rectal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy Followed by Total Mesorectal Excision.新辅助放化疗后癌胚抗原(CEA)和糖类抗原199(CA199)浓度变化的联合检测可预测接受新辅助放化疗后行全直肠系膜切除术的II/III期直肠癌患者的预后。
Cancer Manag Res. 2022 Sep 29;14:2933-2944. doi: 10.2147/CMAR.S377784. eCollection 2022.
6
Pre-Treatment Computed Tomography Radiomics for Predicting the Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer: A Retrospective Study.治疗前计算机断层扫描影像组学预测局部晚期直肠癌新辅助放化疗疗效的回顾性研究
Front Oncol. 2022 May 10;12:850774. doi: 10.3389/fonc.2022.850774. eCollection 2022.
7
Neoadjuvant Chemotherapy plus Bevacizumab Combined with Total Mesorectal Excision in Treating Locally Advanced Rectal Cancer Patients with BRAF Mutation: Clinical Benefit and Safety.新辅助化疗联合贝伐珠单抗联合全直肠系膜切除术治疗伴有 BRAF 突变的局部晚期直肠癌患者:临床获益和安全性。
Comput Math Methods Med. 2021 Dec 9;2021:4227650. doi: 10.1155/2021/4227650. eCollection 2021.
8
Pretreatment Neutrophil-to-Lymphocyte Ratio Associated with Tumor Recurrence and Survival in Patients Achieving a Pathological Complete Response Following Neoadjuvant Chemoradiotherapy for Rectal Cancer.新辅助放化疗后达到病理完全缓解的直肠癌患者,治疗前中性粒细胞与淋巴细胞比值与肿瘤复发及生存的关系
Cancers (Basel). 2021 Sep 13;13(18):4589. doi: 10.3390/cancers13184589.
9
Nomogram to Predict Distant Metastasis Probability for Pathological Complete Response Rectal Cancer Patients After Neoadjuvant Chemoradiotherapy.预测新辅助放化疗后病理完全缓解直肠癌患者远处转移概率的列线图
Cancer Manag Res. 2021 Jun 15;13:4751-4761. doi: 10.2147/CMAR.S313113. eCollection 2021.
10
Resistance to Cell Death in Mucinous Colorectal Cancer-A Review.黏液性结直肠癌中对细胞死亡的抵抗——综述
Cancers (Basel). 2021 Mar 19;13(6):1389. doi: 10.3390/cancers13061389.